Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218185 · ClinicalTrials.gov registry record
Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage
A clinical trial, sponsored by Cerus Corporation.
- Not yet
- Registry status
- 320
- Enrollment target
NCT07218185 is a clinical trial that has not yet begun recruiting, run by Cerus Corporation. The registered enrollment target is 320 participants.
The verdict
NCT07218185 has not yet begun recruiting, sponsored by Cerus Corporation.
- NOT YET RECRUITING
- Registry status
- 320 participants
- Enrollment target
Study Summary
The objective of this multicenter, single-arm, observational study is to determine the feasibility and effectiveness of early administration of FDA-approved, pre-thawed Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex, IFC) in trauma patients with hemorrhagic shock (HS) and functional hypofibrinogenemia. This study will determine whether rapid point-of-care testing for functional hypofibrinogenemia and availability of a shelf-stable fibrinogen complex (IFC) results in shorter time to administration of fibrinogen replacement and correction of functional hypofibrinogenemia, as compared with historical controls and published literature using conventional cryoprecipitate-AHF (CRYO-AHF). This study aims to: * Demonstrate the feasibility and response to early administration of pre-thawed IFC when ordered during initial resuscitation of severely injured patients with HS and functional hypofibrinogenemia. * Assess the effectiveness of early administration of pre-thawed IFC on correction of functional hypofibrinogenemia and on proximate process measures of resuscitation, including time to hemostasis, time to completion of resuscitation, and total volume of resuscitation. * Assess clinical outcomes in severely injured patients with HS and functional hypofibrinogenemia receiving early administration of pre-thawed IFC.
Interventions
- BIOLOGICAL Pathogen Reduced Cryoprecipitated Fibrinogen Complex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07218185
The ClinicalTrials.gov registry entry for NCT07218185 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerus Corporation, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pathogen Reduced Cryoprecipitated Fibrinogen Complex is the first listed.
NCT07218185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07218185 about?
NCT07218185 is a clinical study titled "Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage". The objective of this multicenter, single-arm, observational study is to determine the feasibility and effectiveness of early administration of FDA-approved, pre-thawed Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex, IFC) in trauma patients with hemorrhagic shock ...
What is the current status of trial NCT07218185?
This trial is currently not yet recruiting. The enrollment target is 320 participants. The study started on 2026-07. Estimated completion is 2028-08.
What interventions are being tested in trial NCT07218185?
The interventions under investigation include: Pathogen Reduced Cryoprecipitated Fibrinogen Complex (BIOLOGICAL).
Who is sponsoring clinical trial NCT07218185?
This trial is sponsored by Cerus Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.